CAMPO, E., F. CYMBALISTA, P. GHIA, U. JAGER, Šárka POSPÍŠILOVÁ, R. ROSENQUIST, A. SCHUH and S. STILGENBAUER. TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. haematologica. PAVIA: FERRATA STORTI FOUNDATION, 2018, vol. 103, No 12, p. 1956-1968. ISSN 0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2018.187583. |
Other formats:
BibTeX
LaTeX
RIS
@article{1507037, author = {Campo, E. and Cymbalista, F. and Ghia, P. and Jager, U. and Pospíšilová, Šárka and Rosenquist, R. and Schuh, A. and Stilgenbauer, S.}, article_location = {PAVIA}, article_number = {12}, doi = {http://dx.doi.org/10.3324/haematol.2018.187583}, keywords = {IN-SITU HYBRIDIZATION; OPEN-LABEL; MUTATION ANALYSIS; DISEASE PROGRESSION; CLONAL EVOLUTION; FOLLOW-UP; GENETIC-CHARACTERIZATION; GENOMIC ABERRATIONS; RECURRENT MUTATIONS; SEQUENCE VARIANTS}, language = {eng}, issn = {0390-6078}, journal = {haematologica}, title = {TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics}, volume = {103}, year = {2018} }
TY - JOUR ID - 1507037 AU - Campo, E. - Cymbalista, F. - Ghia, P. - Jager, U. - Pospíšilová, Šárka - Rosenquist, R. - Schuh, A. - Stilgenbauer, S. PY - 2018 TI - TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics JF - haematologica VL - 103 IS - 12 SP - 1956-1968 EP - 1956-1968 PB - FERRATA STORTI FOUNDATION SN - 03906078 KW - IN-SITU HYBRIDIZATION KW - OPEN-LABEL KW - MUTATION ANALYSIS KW - DISEASE PROGRESSION KW - CLONAL EVOLUTION KW - FOLLOW-UP KW - GENETIC-CHARACTERIZATION KW - GENOMIC ABERRATIONS KW - RECURRENT MUTATIONS KW - SEQUENCE VARIANTS N2 - Chronic lymphocytic leukemia is associated with a highly heterogeneous disease course in terms of clinical outcomes and responses to chemoimmunotherapy. This heterogeneity is partly due to genetic aberrations identified in chronic lymphocytic leukemia cells such as mutations of TP53 and/or deletions in chromosome 17p [del(17p)], resulting in loss of one TP53 allele. These aberrations are associated with markedly decreased survival and predict impaired response to chemoimmunotherapy thus being among the strongest predictive markers guiding treatment decisions in chronic lymphocytic leukemia. Clinical trials demonstrate the importance of accurately testing for TP53 aberrations [both del(17p) and TP53mutations] before each line of treatment to allow for appropriate treatment decisions that can optimize patients' outcomes. The current report reviews the diagnostic methods to detect TP53 disruption better, the role of TP53 aberrations in treatment decisions and current therapies available for patients with chronic lymphocytic leukemia carrying these abnormalities. The standardization in sequencing technologies for accurate identification of TP53 mutations and the importance of continued evaluation of TP53 aberrations throughout initial and subsequent lines of therapy remain unmet clinical needs as new therapeutic alternatives become available. ER -
CAMPO, E., F. CYMBALISTA, P. GHIA, U. JAGER, Šárka POSPÍŠILOVÁ, R. ROSENQUIST, A. SCHUH and S. STILGENBAUER. TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. \textit{haematologica}. PAVIA: FERRATA STORTI FOUNDATION, 2018, vol.~103, No~12, p.~1956-1968. ISSN~0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2018.187583.
|